CAR-T therapy for autoimmune diseases: study withdrawn before starting
NCT ID NCT07152223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a new cell therapy (CD19-BCMA CAR-T) for people with connective tissue diseases like lupus and rheumatoid arthritis. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dongguan Taixin Hospital
Dongguan, Guangdong, 523125, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a new biologic tame lupus flares?